KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacira BioSciences (PCRX) Gross Margin (2016 - 2026)

Pacira BioSciences has reported Gross Margin over the past 17 years, most recently at 79.47% for Q1 2026.

  • For Q1 2026, Gross Margin fell 22.0% year-over-year to 79.47%; the TTM value through Mar 2026 reached 79.34%, up 172.0%, while the annual FY2025 figure was 79.39%, 370.0% up from the prior year.
  • Gross Margin for Q1 2026 was 79.47% at Pacira BioSciences, roughly flat from 79.53% in the prior quarter.
  • Over five years, Gross Margin peaked at 112.91% in Q4 2022 and troughed at 69.43% in Q1 2023.
  • A 5-year average of 77.63% and a median of 76.95% in 2024 define the central range for Gross Margin.
  • Biggest five-year swings in Gross Margin: skyrocketed 3741bps in 2022 and later crashed -3922bps in 2023.
  • Year by year, Gross Margin stood at 112.91% in 2022, then crashed by -35bps to 73.69% in 2023, then increased by 7bps to 78.7% in 2024, then rose by 1bps to 79.53% in 2025, then fell by 0bps to 79.47% in 2026.
  • Business Quant data shows Gross Margin for PCRX at 79.47% in Q1 2026, 79.53% in Q4 2025, and 80.91% in Q3 2025.